The results of a beautifully designed and executed trial, testing the effects of fampridine on internuclear ophthalmoparesis (INO) in multiple sclerosis (MS), are now available. In conclusion, fampridine improves saccadic eye movements due to INO in MS. Treatment response to fampridine may gauge patient selection for inclusion to remyelination strategies in MS using saccadic eye movements as primary outcome measure.
Full open article below:
https://www.ncbi.nlm.nih.gov/pubmed/30756475